Literature DB >> 16828490

Role of dietary salt in hypertension.

Francis J Haddy1.   

Abstract

Certain things have not changed since my colleague and I last reviewed the role of dietary salt in hypertension [Haddy, F.J., Pamnani, M.B., 1995. Role of dietary salt in hypertension. Journal of the American College of Nutrition 14, 428-438]. Over half of hypertensives are still salt sensitive, i.e., they respond to a high NaCl intake with a rise in blood pressure. This can be ameliorated by restricting NaCl intake, supplementing potassium intake, and consuming diuretics. Some things have changed. We now have more insight into mechanism; we suspected that volume expansion and endogenous Na(+),K(+)-ATPase inhibitors were the connection between excessive salt intake and the hypertension, but we were not certain as to the nature of the inhibitors. Now it appears that the inhibitors are steroids released from the adrenal gland and are members of the cardenolide family, e.g., ouabain, and the bufadienolide family, e.g., marinobufagenin. This presents new possibilities in therapy, including antibodies to these agents and competitive inhibitors to their binding to Na(+),K(+)-ATPase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16828490     DOI: 10.1016/j.lfs.2006.05.017

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  27 in total

1.  Sympathetic nerves and the endothelium influence the vasoconstrictor effect of low concentrations of ouabain in pressurized small arteries.

Authors:  Hema Raina; Qingli Zhang; Albert Y Rhee; Thomas L Pallone; W Gil Wier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

2.  Heavy metal contents of refined and unrefined table salts from Turkey, Egypt and Greece.

Authors:  Mustafa Soylak; Dondu Serpil Kacar Peker; Orhan Turkoglu
Journal:  Environ Monit Assess       Date:  2007-09-16       Impact factor: 2.513

3.  Ouabain-Sensitive alpha1 Na,K-ATPase enhances natriuretic response to saline load.

Authors:  Elizabeth L Loreaux; Baksho Kaul; John N Lorenz; Jerry B Lingrel
Journal:  J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 10.121

Review 4.  Endogenous digitalis: pathophysiologic roles and therapeutic applications.

Authors:  Alexei Y Bagrov; Joseph I Shapiro
Journal:  Nat Clin Pract Nephrol       Date:  2008-06-10

Review 5.  Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.

Authors:  Alexei Y Bagrov; Joseph I Shapiro; Olga V Fedorova
Journal:  Pharmacol Rev       Date:  2009-03       Impact factor: 25.468

6.  Ouabain-stimulated trafficking regulation of the Na/K-ATPase and NHE3 in renal proximal tubule cells.

Authors:  Yanling Yan; Steven Haller; Anna Shapiro; Nathan Malhotra; Jiang Tian; Zijian Xie; Deepak Malhotra; Joseph I Shapiro; Jiang Liu
Journal:  Mol Cell Biochem       Date:  2012-05-23       Impact factor: 3.396

Review 7.  Biochemical interaction of salt sensitivity: a key player for the development of essential hypertension.

Authors:  Imran Kazmi; Waleed Hassan Al-Maliki; Haider Ali; Fahad A Al-Abbasi
Journal:  Mol Cell Biochem       Date:  2020-10-18       Impact factor: 3.396

Review 8.  A role for benzamil-sensitive proteins of the central nervous system in the pathogenesis of salt-dependent hypertension.

Authors:  Joanna M Abrams; John W Osborn
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-05       Impact factor: 2.557

9.  Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial.

Authors:  Eduardo Pimenta; Krishna K Gaddam; Suzanne Oparil; Inmaculada Aban; Saima Husain; Louis J Dell'Italia; David A Calhoun
Journal:  Hypertension       Date:  2009-07-20       Impact factor: 10.190

10.  Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.

Authors:  Lama Ghazi; Tanja Dudenbostel; Chee Paul Lin; Suzanne Oparil; David A Calhoun
Journal:  J Hypertens       Date:  2016-05       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.